New pill aims to slow deadly lung scarring in IPF patients
Disease control
Recruiting now
This study tests an oral medication called ifetroban in 128 adults aged 40+ with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants will receive either ifetroban or a placebo for 52 weeks to see if the drug can slow the decline in lung function…
Phase: PHASE2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:05 UTC